The research tackles a stubborn gap in genetics. Genome-wide association studies have linked hundreds of DNA variants to obesity and cardiometabolic disease, but most of these variants sit in stretches of the genome that do not code for proteins. Interpreting them has been notoriously difficult, in part because the relevant regulatory effects often operate in specific cell types and often influence genes located far away on the genome, not just their immediate neighbors. Traditional bulk tissue studies, which average signals across many cell types, tend to wash out these cell-specific effects, leaving the biological story hidden in the noise.

To cut through that noise, the team turned to single nucleus RNA-sequencing of human subcutaneous adipose tissue biopsies. Rather than measuring average gene expression across a whole tissue sample, this technology profiles the transcriptomes of individual nuclei, allowing researchers to distinguish adipocytes from adipose stem and progenitor cells, immune cells and other residents of fat tissue. With this resolution, the investigators first asked a foundational question: how much of the inherited risk for cardiometabolic disease can be traced to regulatory activity around genes that mark specific fat-tissue cell types?

The answer was striking. The team found that the heritability of epigenetic sites surrounding adipocyte marker genes in subcutaneous adipose tissue was significantly enriched for abdominal obesity, the pattern of fat accumulation around the abdomen that carries the strongest cardiometabolic risk. These cell-type marker genes were also enriched for central pathways of adipocyte function, suggesting that the genes that define a fat cell as a fat cell are precisely the genes where obesity-related genetic risk concentrates. In other words, the genetic architecture of obesity appears to be written, in large part, into the core identity of the adipocyte itself.

With the cell-type landscape mapped, the researchers searched for transcription factors, the proteins that bind DNA and switch genes on or off, encoded within the functional pathways of the adipocyte marker genes. One name rose above the rest: SREBF1, which encodes sterol regulatory element-binding transcription factor 1, a long-recognized master regulator of fat synthesis and lipid metabolism. SREBF1 emerged as the most frequently represented transcription factor across these adipocyte pathways, making it a prime candidate for deeper genetic scrutiny.

That scrutiny centered on a variant called rs8079321, a DNA change already flagged by genome-wide association studies as associated with abdominal obesity and type 2 diabetes. The team showed that this variant regulates SREBF1 expression in cis, meaning it alters the activity of the SREBF1 gene itself, which sits nearby on the genome. Such cis effects are the bread and butter of expression quantitative trait locus studies, which link genetic variants to differences in gene expression. But the researchers went a crucial step further, asking whether a variant that dials SREBF1 up or down might also, through the transcription factor’s own activity, change the expression of the many genes SREBF1 controls, effects that would occur in trans, across the genome.

To test this, the investigators examined adipocyte-specific expression in single nucleus RNA-sequencing data and then verified their findings in an independent cohort of subcutaneous adipose tissue single nucleus RNA-sequencing samples. The result held up: the risk allele of rs8079321 affected adipocyte expression of SREBF1 in cis and, remarkably, the expression of 89 adipocyte marker genes in trans. Nearly one hundred genes, all markers of the fat cell’s core identity, shifted their expression depending on which version of this single variant a person carried. This is allele-specific trans regulation at scale, and it had been verified in human tissue rather than inferred from cell lines or animal models.

The final and arguably most consequential step connected these molecular effects to disease risk at the population level. Using data from the UK Biobank, a research resource containing genetic and health information from hundreds of thousands of participants, the team constructed partitioned polygenic risk scores for abdominal obesity and type 2 diabetes, focusing specifically on the 89 trans-regulated genes. They found that these partitioned risk scores differed depending on which allele of rs8079321 individuals carried. The implication is profound: the trans effects observed at the level of individual fat cell transcripts extend upward to shape polygenic risk for highly common cardiometabolic diseases.

This chain of evidence, from a single regulatory variant, through a master transcription factor, to a coordinated program of gene expression in a specific cell type, and finally to measurable differences in inherited disease risk, illustrates a mechanism that may underlie far more of the missing heritability of complex disease than previously appreciated. If variants like rs8079321 can exert allele-specific control over whole gene programs in key cell types, then many genome-wide association signals that currently point to anonymous stretches of DNA may in fact be pointing to cis-regulated transcription factors whose real impact lies in the trans programs they govern. The study’s authors suggest that integrating single-cell omics with biobank data, as they did here, offers a generalizable strategy for identifying such human trans-expression quantitative trait locus genes.

The work also carries practical weight for a world grappling with obesity. With global obesity prevalence high and mechanistic, cell-type-level knowledge of predisposing genes still limited, pinpointing SREBF1 as an allele-specific hub of adipocyte regulation gives researchers a concrete molecular node to study. It suggests that the path from genetic risk to metabolic disease may run through the transcriptional identity of the fat cell itself, and that interventions aimed at modulating SREBF1 activity, or the pathways it controls in adipocytes, could one day help blunt the impact of risk variants that millions of people carry. For now, the study stands as a technical tour de force and a template: by looking at disease genetics one cell type at a time, researchers are beginning to read the fine print of the human genome that bulk studies have long blurred over.

Subject of Research: Allele-specific trans regulation of adipocyte gene expression by SREBF1 and its relationship to cardiometabolic disease risk

Article Title: Integration of single cell omics with biobank data discovers allele-specific trans effects of SREBF1 on adipocyte expression of nearly 100 genes

Article References: Integration of single cell omics with biobank data discovers allele-specific trans effects of SREBF1 on adipocyte expression of nearly 100 genes. (n.d.). https://doi.org/10.1186/s13073-026-01790-z

Image Credits: AI Generated

DOI: 10.1186/s13073-026-01790-z

Keywords: SREBF1, adipocytes, single nucleus RNA-sequencing, trans-eQTL, subcutaneous adipose tissue, abdominal obesity, type 2 diabetes, polygenic risk score, GWAS, transcription factors, gene regulation, UK Biobank